Deals In Depth: June/July 2012
Walgreen took a 45% stake in Alliance Boots for $6.6 billion. BMS boosted its diabetes portfolio by paying $6.8 billion for Amylin, while German device manufacturer BSN Medical was bought out by EQT for $2.2 billion. Biopharma financing totaled $713 million and $1.3 billion in June and July, respectively. Device fundraising decreased, going from $352 million in June to $126 million the following month.